The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.
Richard D Baird
No relevant relationships to disclose
Sophie Papa
No relevant relationships to disclose
Nicola Cresti
No relevant relationships to disclose
Helen Hatcher
No relevant relationships to disclose
Linda Hogarth
No relevant relationships to disclose
Mariam Jamal-Hanjani
No relevant relationships to disclose
Eugene P. Frenkel
Consultant or Advisory Role - Project Manager Strategic Development Department
Kirsteen Donaldson
Consultant or Advisory Role - Shionogi and Co. Ltd.
John Posner
Consultant or Advisory Role - Shionogi and Co. Ltd.
Izumi Kawabata
Employment or Leadership Position - Shionogi and Co. Ltd.
Duncan Ian Jodrell
No relevant relationships to disclose
Ruth Plummer
No relevant relationships to disclose
James F. Spicer
No relevant relationships to disclose